Verrica Pharmaceuticals Reports Promising Phase 2 Results for VP-315 in Basal Cell Carcinoma
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced this week that Part 2 of its Phase 2 clinical trial for VP-315, a potential first-in-class oncolytic peptide, has yielded …
Verrica Pharmaceuticals Reports Promising Phase 2 Results for VP-315 in Basal Cell Carcinoma Read More